Who We Are
Built on 80 years of experience, SK pharmteco is a trusted partner specializing in the manufacture of APIs and intermediates, viral vectors for gene and cell therapies, registered starting materials and analytical services for the pharmaceutical industry worldwide. Our global operations have the capability and capacity to support your needs from development through commercial production.
Our complementary assets and expertise enable us to provide the highest quality services to our customers.
SK pharmteco specializes in the commercial and clinical production of APIs, Advanced Intermediates, Registered Starting Materials, Key Building Blocks and Viral Vectors. Our offerings include process R&D, analytical method development and stability, scale-up and optimization, validation and commercial production. Additionally, we offer extensive Adeno-Associated Viral (AAV) and Lentiviral vector development and cGMP production capabilities.
Our global operations include 7 cGMP manufacturing and development facilities across the United States, Korea, Ireland and France. We also operate a dedicated analytical services facility.
SK pharmteco is a leader in operational excellence and continuous improvement. Our highly skilled team delivers innovative solutions utilizing advanced technologies:
- Energetic Chemistry
- Continuous Flow Processing
- Chromatography: Simulated Moving Bed (SMB) & Batch
- High Potency (Up to 4 m3 scale & Down to 10 ng/m3 containment)
- Controlled Substances (Schedule II-V Manufacturing)
- Particle Engineering
- cGMP Manufacturing in Adherent & Suspension Systems for Viral Vectors
- Analytical & Process Development for Viral Vectors
We provide PAI and full regulatory support as well as complete confidentiality. We have a strong record of environmental, health, and safety performance. All our plants have been successfully audited by global regulatory agencies including the FDA (US), EMA (Europe), PMDA (Japan), and MFDS (Korea).
With a strong technology toolbox and ~1,000 m³ (~265,000 gal) of global small-molecule capacity plus a 5,000 m² facility dedicated to large molecules, we have the capability and capacity to support your needs across the full lifecycle.
7 Manufacturing Sites
~1,000 m³ (~265,000 gal)
Small Molecule Production Capacity
3 US (589 m³), 2 Korea (276 m³), 1 Ireland (97 m³)
5,000 m² Facility for
Large Molecule Manufacturing
1 France (expanding to 10,000 m²)
3 R&D Centers
Ireland, US, Korea
80 Years of Experience
1,500+ Highly Skilled and Talented Workforce
approved by global regulatory agencies
FDA, EMA, ANSM, PMDA, MFDS
Diazomethane, Azide, Hydrazine, Ozone
Fixed bed, CSTR, PAT
Simulated Moving Bed (SMB), Batch
Up to 4 m3 (~1,000 gal) scale
Down to 10 ng/m3 containment
Schedule II-V Manufacturing
Schedule I By Request
In February’s issue ChemistryToday Brian Mullan Yposkesi’s Head of Development & Innovation has published an article on how C> are
Link to Original Post: https://www.linkedin.com/posts/sk-group-media_mysk-activity-6889210467521196032-pLZT